Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Heysol C Bermudez-Cabrera"'
Autor:
Heysol C. Bermudez-Cabrera, Sannie Culbertson, Sammy Barkal, Benjamin Holmes, Max W. Shen, Sophia Zhang, David K. Gifford, Richard I. Sherwood
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-10 (2021)
The mutational outcome of CRISPR-Cas9 editing can be both predictable and targeted. Here the authors show that ATM inhibitor KU-60019 increases 1 bp insertions at the targeted locus.
Externí odkaz:
https://doaj.org/article/77675116590e4b8aa7e1d10c6a4309b0
Autor:
Vedagopuram Sreekanth, Qingxuan Zhou, Praveen Kokkonda, Heysol C. Bermudez-Cabrera, Donghyun Lim, Benjamin K. Law, Benjamin R. Holmes, Santosh K. Chaudhary, Rajaiah Pergu, Brittany S. Leger, James A. Walker, David K. Gifford, Richard I. Sherwood, Amit Choudhary
Publikováno v:
ACS Central Science, Vol 6, Iss 12, Pp 2228-2237 (2020)
Externí odkaz:
https://doaj.org/article/f59a8cf4db8b44faa234b0cf6a54c506
Autor:
Richard I. Sherwood, Sammy A Barkal, Sannie J. Culbertson, Sophia Zhang, Heysol C Bermudez-Cabrera, Max W. Shen, Benjamin Holmes, David K. Gifford
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-10 (2021)
Nature Communications
Nature Communications
Mutational outcomes following CRISPR-Cas9-nuclease cutting in mammalian cells have recently been shown to be predictable and, in certain cases, skewed toward single genotypes. However, the ability to control these outcomes remains limited, especially
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e49ed019225d0508ad5181b877277d0
https://doi.org/10.1038/s41467-021-25415-8
https://doi.org/10.1038/s41467-021-25415-8
Autor:
Marisa C Hamilton, Minja Velimirovic, Grace Hui Ting Yeo, Sammy A Barkal, Miha Sovrovic, Maggie S Chen, James D. Fife, Benyapa Khowpinitchai, Larissa C. Zanetti, Ersin Akinci, Lin Lin, Rikita Jodhani, Callie J Donahue, Minsun Cha, Richard I. Sherwood, Philip A. Cole, Nam Chu, Robert A. Davey, Christopher A. Cassa, Heysol C Bermudez-Cabrera
Publikováno v:
bioRxiv
article-version (status) pre
article-version (number) 1
article-version (status) pre
article-version (number) 1
The adenosine analogue remdesivir has emerged as a frontline antiviral treatment for SARS-CoV-2, with preliminary evidence that it reduces the duration and severity of illness1. Prior clinical studies have identified adverse events1,2, and remdesivir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1eb88bab26c658dee707769080085330
https://doi.org/10.1101/2020.08.27.270819
https://doi.org/10.1101/2020.08.27.270819
